title: Severe high-density lipoprotein deficiency associated with autoantibodies against lecithin:cholesterol acyltransferase in non-Hodgkin lymphoma.
abstract: An antibody against the lecithin:cholesterol acyltransferase (LCAT) enzyme, which negates cholesterol esterification in plasma, causing severe high-density lipoprotein deficiency (HD), was identified in a woman with a large-cell non-Hodgkin lymphoma. Successful treatment of the lymphoma resulted in clearance of the antibody and complete correction of the defective cholesterol esterification and HD. To our knowledge, an acquired LCAT deficiency leading to severe HD has not been reported previously in association with a malignant disease, and this patient represents the first such documented case.
authors.affiliation: Department of Pharmacological Sciences, Università degli Studi di Milano, 20133 Milano, Italy.
authors.forename: Sara
authors.initials: S
authors.lastname: Simonelli
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Gianazza
authors.forename: Giuliana
authors.initials: G
authors.lastname: Mombelli
authors.forename: Alighiero
authors.initials: A
authors.lastname: Bondioli
authors.forename: Giovanni
authors.initials: G
authors.lastname: Ferraro
authors.forename: Silvana
authors.initials: S
authors.lastname: Penco
authors.forename: Cesare R
authors.initials: CR
authors.lastname: Sirtori
authors.forename: Guido
authors.initials: G
authors.lastname: Franceschini
authors.forename: Laura
authors.initials: L
authors.lastname: Calabresi
mesh_terms: D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016632:Apolipoprotein A-I / Q000097:blood; D016633:Apolipoprotein A-II / Q000097:blood; D001323:Autoantibodies / Q000097:blood*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D008075:Lipoproteins, HDL / Q000097:blood / Q000172:deficiency*; D008077:Lipoproteins, LDL / Q000097:blood; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis* / Q000188:drug therapy; D007862:Phosphatidylcholine-Sterol O-Acyltransferase / Q000097:blood / Q000276:immunology*; D011241:Prednisone / Q000627:therapeutic use; D000069283:Rituximab; D012720:Severity of Illness Index; D014280:Triglycerides / Q000097:blood; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D016632:Apolipoprotein A-I; D016633:Apolipoprotein A-II; D001323:Autoantibodies; D007074:Immunoglobulin G; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D014280:Triglycerides; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D007862:Phosphatidylcholine-Sterol O-Acyltransferase; D011241:Prednisone